Acrux Lifts Cash and Revenue as It Refocuses Portfolio on Higher-Value Therapies

The latest announcement is out from Acrux ( (AU:ACR) ).

Acrux reported a solid December 2025 quarter, with customer receipts rising to $1.807 million and cash and cash equivalents increasing to $0.946 million, supported by strong growth in profit-share and royalty income as its U.S. topical generics portfolio completed its first full revenue periods since launch. The company strengthened its portfolio by divesting the underperforming Prilocaine/Lidocaine cream—which generated $0.822 million and removed associated liabilities—while expanding fee-for-service work for external partners, tightening operating costs, and reallocating R&D spending from mature generics toward higher-potential HRT and next-generation drug delivery programs, moves that collectively aim to bolster margins, de-risk returns in a competitive U.S. generics market, and reposition Acrux for longer-term growth.

The most recent analyst rating on (AU:ACR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Acrux stock, see the AU:ACR Stock Forecast page.

More about Acrux

Acrux Limited is an Australian specialty topical pharmaceuticals company focused on developing and commercialising generic and innovative topical drugs, primarily for the U.S. market. Its portfolio currently includes four marketed products in the United States—Evamist estradiol spray for menopause symptoms, Dapsone 5% and 7.5% gels for acne vulgaris, and Nitroglycerin 0.4% ointment for chronic anal fissure pain—while it also pursues international registrations and new opportunities in female hormone replacement therapy (HRT) and other therapeutic areas leveraging its drug delivery expertise.

Average Trading Volume: 271,235

Technical Sentiment Signal: Sell

Current Market Cap: A$6.16M

Learn more about ACR stock on TipRanks’ Stock Analysis page.